-
1
-
-
77955635233
-
Cancer statistics, 2010
-
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60 (5), 277 –300 (2010).
-
(2010)
CA Cancer J. Clin.
, vol.60
, Issue.5
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
2
-
-
77950366767
-
BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control
-
Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev. Vaccines 9 (2), 209 –222 (2010).
-
(2010)
Expert Rev. Vaccines
, vol.9
, Issue.2
, pp. 209-222
-
-
Merle, C.S.1
Cunha, S.S.2
Rodrigues, L.C.3
-
3
-
-
0037323336
-
The effect of bacille Calmette–Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS
-
Paolillo A, Buzzi MG, Giugni E et al. The effect of bacille Calmette–Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS. J. Neurol. 250 (2), 247 –248 (2003).
-
(2003)
J. Neurol.
, vol.250
, Issue.2
, pp. 247-248
-
-
Paolillo, A.1
Buzzi, M.G.2
Giugni, E.3
-
4
-
-
79960677601
-
Fact and fiction in tuberculosis vaccine research: 10 years later
-
Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect. Dis. 11 (8), 633 –640 (2011).
-
(2011)
Lancet Infect. Dis.
, vol.11
, Issue.8
, pp. 633-640
-
-
Kaufmann, S.H.1
-
5
-
-
75149136162
-
Bacillus Calmette–Guérin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy
-
Yuk JM, Shin DM, Song KS et al. Bacillus Calmette–Guérin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. Autophagy 6 (1), 46 –60 (2010).
-
(2010)
Autophagy
, vol.6
, Issue.1
, pp. 46-60
-
-
Yuk, J.M.1
Shin, D.M.2
Song, K.S.3
-
6
-
-
78751641748
-
Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer
-
Weizer AZ, Tallman C, Montgomery JS. Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. World J. Urol. 29 (1), 59 –71 (2010).
-
(2010)
World J. Urol.
, vol.29
, Issue.1
, pp. 59-71
-
-
Weizer, A.Z.1
Tallman, C.2
Montgomery, J.S.3
-
7
-
-
0017116422
-
Intralesional immunotherapy of melanoma with BCG
-
Rosenberg SA, Rapp HJ. Intralesional immunotherapy of melanoma with BCG. Med. Clin. North Am. 60 (3), 419 –430 (1976).
-
(1976)
Med. Clin. North Am.
, vol.60
, Issue.3
, pp. 419-430
-
-
Rosenberg, S.A.1
Rapp, H.J.2
-
8
-
-
0026032351
-
Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis
-
de Boer EC, de Jong WH, van der Meijden AP et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol. Res. 19 (1), 45 –50 (1991).
-
(1991)
Urol. Res.
, vol.19
, Issue.1
, pp. 45-50
-
-
de Boer, E.C.1
de Jong, W.H.2
van der, M.A.3
-
10
-
-
2442710545
-
Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette–Guérin-induced antitumor activity
-
Ludwig AT, Moore JM, Luo Y et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette–Guérin-induced antitumor activity. Cancer Res. 64 (10), 3386 –3390 (2004).
-
(2004)
Cancer Res.
, vol.64
, Issue.10
, pp. 3386-3390
-
-
Ludwig, A.T.1
Moore, J.M.2
Luo, Y.3
-
11
-
-
0036499079
-
Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon α-2b for high-risk melanoma patients using intergroup clinical trial data
-
Kilbridge KL, Cole BF, Kirkwood JM et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon α-2b for high-risk melanoma patients using intergroup clinical trial data. J. Clin. Oncol. 20 (5), 1311 –1318 (2002).
-
(2002)
J. Clin. Oncol.
, vol.20
, Issue.5
, pp. 1311-1318
-
-
Kilbridge, K.L.1
Cole, B.F.2
Kirkwood, J.M.3
-
12
-
-
0141817861
-
Impact of vaccinations and infectious diseases on the risk of melanoma – evaluation of an EORTC case–control study
-
Krone B, Kolmel KF, Grange JM et al. Impact of vaccinations and infectious diseases on the risk of melanoma – evaluation of an EORTC case–control study. Eur. J. Cancer 39 (16), 2372 –2378 (2003).
-
(2003)
Eur. J. Cancer
, vol.39
, Issue.16
, pp. 2372-2378
-
-
Krone, B.1
Kolmel, K.F.2
Grange, J.M.3
-
13
-
-
0026778718
-
Febrile infections and malignant melanoma: results of a case–control study
-
Kolmel KF, Gefeller O, Haferkamp B. Febrile infections and malignant melanoma: results of a case–control study. Melanoma Res. 2 (3), 207 –211 (1992).
-
(1992)
Melanoma Res.
, vol.2
, Issue.3
, pp. 207-211
-
-
Kolmel, K.F.1
Gefeller, O.2
Haferkamp, B.3
-
14
-
-
19944383121
-
Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients
-
Kolmel KF, Grange JM, Krone B et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur. J. Cancer 41 (1), 118 –125 (2005).
-
(2005)
Eur. J. Cancer
, vol.41
, Issue.1
, pp. 118-125
-
-
Kolmel, K.F.1
Grange, J.M.2
Krone, B.3
-
15
-
-
18544377660
-
Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study
-
Pfahlberg A, Kolmel KF, Grange JM et al. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J. Invest. Dermatol. 119 (3), 570 –575 (2002).
-
(2002)
J. Invest. Dermatol.
, vol.119
, Issue.3
, pp. 570-575
-
-
Pfahlberg, A.1
Kolmel, K.F.2
Grange, J.M.3
-
16
-
-
1842582038
-
Mature results of a Phase III randomized trial of bacillus Calmette–Guérin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I-III melanoma (E1673): a trial of the Eastern Oncology Group
-
Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a Phase III randomized trial of bacillus Calmette–Guérin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100 (8), 1692 –1698 (2004).
-
(2004)
Cancer
, vol.100
, Issue.8
, pp. 1692-1698
-
-
Agarwala, S.S.1
Neuberg, D.2
Park, Y.3
Kirkwood, J.M.4
-
17
-
-
0025858804
-
Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a Phase III study by the National Cancer Institute of Canada Clinical Trials Group
-
Quirt IC, Shelley WE, Pater JL et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a Phase III study by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 9 (5), 729 –735 (1991).
-
(1991)
J. Clin. Oncol.
, vol.9
, Issue.5
, pp. 729-735
-
-
Quirt, I.C.1
Shelley, W.E.2
Pater, J.L.3
-
18
-
-
0024556019
-
The significance of conversion of skin reactivity to efficacy of bacillus Calmette–Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients
-
Cascinelli N, Rumke P, MacKie R, Morabito A, Bufalino R. The significance of conversion of skin reactivity to efficacy of bacillus Calmette–Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol. Immunother. 28 (4), 282 –286 (1989).
-
(1989)
Cancer Immunol. Immunother.
, vol.28
, Issue.4
, pp. 282-286
-
-
Cascinelli, N.1
Rumke, P.2
MacKie, R.3
Morabito, A.4
Bufalino, R.5
-
19
-
-
34548249596
-
An international, randomized, Phase III Trial of bacillus Calmette–Guérin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma to regional or distant sites
-
Morton DL, Mozzillo N, Thompson JF et al. An international, randomized, Phase III Trial of bacillus Calmette–Guérin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma to regional or distant sites. J. Clin. Oncol. 2007 ASCO Ann. Meeting Proc. 25 (18 Suppl.), 8508 (2007).
-
(2007)
J. Clin. Oncol. 2007 ASCO Ann. Meeting Proc.
, vol.25
, pp. 8508
-
-
Morton, D.L.1
Mozzillo, N.2
Thompson, J.F.3
-
20
-
-
3042666881
-
An evidence-based staging system for cutaneous melanoma
-
quiz 182–184 (2004).
-
Balch CM, Soong SJ, Atkins MB et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J. Clin. 54 (3), 131 –149; quiz 182–184 (2004).
-
CA Cancer J. Clin.
, vol.54
, Issue.3
, pp. 131-149
-
-
Balch, C.M.1
Soong, S.J.2
Atkins, M.B.3
-
22
-
-
33745635043
-
The stem-cell niche as an entity of action
-
Scadden DT. The stem-cell niche as an entity of action. Nature 441 (7097), 1075 –1079 (2006).
-
(2006)
Nature
, vol.441
, Issue.7097
, pp. 1075-1079
-
-
Scadden, D.T.1
-
23
-
-
33947504062
-
Molecular mechanisms and therapeutic reversal of immune suppression in cancer
-
Gabrilovich DI. Molecular mechanisms and therapeutic reversal of immune suppression in cancer. Curr. Cancer Drug Targets 7 (1), 1 (2007).
-
(2007)
Curr. Cancer Drug Targets
, vol.7
, Issue.1
, pp. 1
-
-
Gabrilovich, D.I.1
-
24
-
-
79959684874
-
Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation
-
Mauti LA, Le Bitoux MA, Baumer K et al. Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J. Clin. Invest. 121 (7), 2794 –2807 (2011).
-
(2011)
J. Clin. Invest.
, vol.121
, Issue.7
, pp. 2794-2807
-
-
Mauti, L.A.1
Le Bitoux, M.A.2
Baumer, K.3
-
25
-
-
79960003585
-
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
-
Raychaudhuri B, Rayman P, Ireland J et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 13 (6), 591 –599 (2011).
-
(2011)
Neuro Oncol.
, vol.13
, Issue.6
, pp. 591-599
-
-
Raychaudhuri, B.1
Rayman, P.2
Ireland, J.3
-
26
-
-
79959966013
-
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer
-
Goedegebuure P, Mitchem JB, Porembka MR et al. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr. Cancer Drug Targets 11 (6), 734 –751 (2011).
-
(2011)
Curr. Cancer Drug Targets
, vol.11
, Issue.6
, pp. 734-751
-
-
Goedegebuure, P.1
Mitchem, J.B.2
Porembka, M.R.3
-
27
-
-
33746040164
-
The inflammatory tumor microenvironment and its impact on cancer development
-
de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib. Microbiol. 13, 118 –137 (2006).
-
(2006)
Contrib. Microbiol.
, vol.13
, pp. 118-137
-
-
de Visser, K.E.1
Coussens, L.M.2
-
28
-
-
79960835345
-
High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer
-
H.E., Lee, D.J., Park, W.H., Kim, H.H., Kim, H.S., Lee, High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer, Br. J. Cancer, (2011), 105, 3, 413-419
-
(2011)
Br. J. Cancer
, vol.105
, Issue.3
, pp. 413-419
-
-
Lee, H.E.1
Park, D.J.2
Kim, W.H.3
Kim, H.H.4
Lee, H.S.5
-
29
-
-
85027940310
-
CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes
-
Liu F, Lang R, Zhao J et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res. Treat. 130 (2), 645 –655 (2011).
-
(2011)
Breast Cancer Res. Treat.
, vol.130
, Issue.2
, pp. 645-655
-
-
Liu, F.1
Lang, R.2
Zhao, J.3
-
30
-
-
38949200291
-
Effect of melanoma on immune function in the regional lymph node basin
-
Negin B, Panka D, Wang W et al. Effect of melanoma on immune function in the regional lymph node basin. Clin. Cancer Res. 14 (3), 654 –659 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, Issue.3
, pp. 654-659
-
-
Negin, B.1
Panka, D.2
Wang, W.3
-
31
-
-
0030030347
-
Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684
-
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14 (1), 7 –17 (1996).
-
(1996)
J. Clin. Oncol.
, vol.14
, Issue.1
, pp. 7-17
-
-
Kirkwood, J.M.1
Strawderman, M.H.2
Ernstoff, M.S.3
Smith, T.J.4
Borden, E.C.5
Blum, R.H.6
-
32
-
-
0034088027
-
High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190
-
Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18 (12), 2444 –2458 (2000).
-
(2000)
J. Clin. Oncol.
, vol.18
, Issue.12
, pp. 2444-2458
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sondak, V.K.3
-
33
-
-
0035339880
-
High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801
-
Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19 (9), 2370 –2380 (2001).
-
(2001)
J. Clin. Oncol.
, vol.19
, Issue.9
, pp. 2370-2380
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sosman, J.A.3
-
34
-
-
7144228601
-
Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma
-
Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351 (9120), 1905 –1910 (1998).
-
(1998)
Lancet
, vol.351
, Issue.9120
, pp. 1905-1910
-
-
Grob, J.J.1
Dreno, B.2
de la Salmoniere, P.3
-
35
-
-
7144264391
-
Adjuvant interferon α-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group
-
Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon α-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J. Clin. Oncol. 16 (4), 1425 –1429 (1998).
-
(1998)
J. Clin. Oncol.
, vol.16
, Issue.4
, pp. 1425-1429
-
-
Pehamberger, H.1
Soyer, H.P.2
Steiner, A.3
-
36
-
-
3242686449
-
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study – United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon α-2a in high-risk resected malignant melanoma
-
Hancock BW, Wheatley K, Harris S et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study – United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon α-2a in high-risk resected malignant melanoma. J. Clin. Oncol. 22 (1), 53 –61 (2004).
-
(2004)
J. Clin. Oncol.
, vol.22
, Issue.1
, pp. 53-61
-
-
Hancock, B.W.1
Wheatley, K.2
Harris, S.3
-
37
-
-
0035805053
-
Adjuvant interferon α 2b in high risk melanoma – the Scottish study
-
Cameron DA, Cornbleet MC, Mackie RM et al. Adjuvant interferon α 2b in high risk melanoma – the Scottish study. Br. J. Cancer 84 (9), 1146 –1149 (2001).
-
(2001)
Br. J. Cancer
, vol.84
, Issue.9
, pp. 1146-1149
-
-
Cameron, D.A.1
Cornbleet, M.C.2
Mackie, R.M.3
-
38
-
-
0035883950
-
Effect of long-term adjuvant therapy with interferon α-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial
-
Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon α-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358 (9285), 866 –869 (2001).
-
(2001)
Lancet
, vol.358
, Issue.9285
, pp. 866-869
-
-
Cascinelli, N.1
Belli, F.2
MacKie, R.M.3
Santinami, M.4
Bufalino, R.5
Morabito, A.6
-
39
-
-
44849131339
-
Adjuvant low-dose interferon {α}2a with or without dacarbazine compared with surgery alone: a prospective-randomized Phase III DeCOG trial in melanoma patients with regional lymph node metastasis
-
Garbe C, Radny P, Linse R et al. Adjuvant low-dose interferon {α}2a with or without dacarbazine compared with surgery alone: a prospective-randomized Phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann. Oncol. 19 (6), 1195 –1201 (2008).
-
(2008)
Ann. Oncol.
, vol.19
, Issue.6
, pp. 1195-1201
-
-
Garbe, C.1
Radny, P.2
Linse, R.3
-
40
-
-
25844465690
-
Post-surgery adjuvant therapy with intermediate doses of interferon α 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
-
Eggermont AM, Suciu S, MacKie R et al. Post-surgery adjuvant therapy with intermediate doses of interferon α 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366 (9492), 1189 –1196 (2005).
-
(2005)
Lancet
, vol.366
, Issue.9492
, pp. 1189-1196
-
-
Eggermont, A.M.1
Suciu, S.2
MacKie, R.3
-
41
-
-
3242734089
-
Tolerability of adjuvant high-dose interferon α-2b: 1 month versus 1 year – a Hellenic Cooperative Oncology Group study
-
Gogas H, Bafaloukos D, Ioannovich J et al. Tolerability of adjuvant high-dose interferon α-2b: 1 month versus 1 year – a Hellenic Cooperative Oncology Group study. Anticancer Res. 24 (3b), 1947 –1952 (2004).
-
(2004)
Anticancer Res.
, vol.24
, Issue.3b
, pp. 1947-1952
-
-
Gogas, H.1
Bafaloukos, D.2
Ioannovich, J.3
-
42
-
-
46749103710
-
Adjuvant therapy with pegylated interferon α-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial
-
Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon α-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial. Lancet 372 (9633), 117 –126 (2008).
-
(2008)
Lancet
, vol.372
, Issue.9633
, pp. 117-126
-
-
Eggermont, A.M.1
Suciu, S.2
Santinami, M.3
-
43
-
-
0025228650
-
Thoracotomy for metastatic malignant melanoma of the lung
-
Karp NS, Boyd A, DePan HJ, Harris MN, Roses DF. Thoracotomy for metastatic malignant melanoma of the lung. Surgery 107 (3), 256 –261 (1990).
-
(1990)
Surgery
, vol.107
, Issue.3
, pp. 256-261
-
-
Karp, N.S.1
Boyd, A.2
DePan, H.J.3
Harris, M.N.4
Roses, D.F.5
-
44
-
-
0026550697
-
Analysis of 945 cases of pulmonary metastatic melanoma
-
discussion 748–750 (1992).
-
Harpole DH, Jr., Johnson CM, Wolfe WG, George SL, Seigler HF. Analysis of 945 cases of pulmonary metastatic melanoma. J. Thorac. Cardiovasc. Surg. 103 (4), 743 –748; discussion 748–750 (1992).
-
J. Thorac. Cardiovasc. Surg.
, vol.103
, Issue.4
, pp. 743-748
-
-
Harpole, D.H.1
Johnson, C.M.2
Wolfe, W.G.3
George, S.L.4
Seigler, H.F.5
-
45
-
-
0025836919
-
Role of surgical intervention in the management of intestinal metastases from malignant melanoma
-
Branum GD, Seigler HF. Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am. J. Surg. 162 (5), 428 –431 (1991).
-
(1991)
Am. J. Surg.
, vol.162
, Issue.5
, pp. 428-431
-
-
Branum, G.D.1
Seigler, H.F.2
-
46
-
-
0028355105
-
Metastasectomy in malignant melanoma
-
Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery 115 (3), 295 –302 (1994).
-
(1994)
Surgery
, vol.115
, Issue.3
, pp. 295-302
-
-
Karakousis, C.P.1
Velez, A.2
Driscoll, D.L.3
Takita, H.4
-
47
-
-
0036896972
-
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine
-
Hsueh EC, Essner R, Foshag LJ et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 20 (23), 4549 –4554 (2002).
-
(2002)
J. Clin. Oncol.
, vol.20
, Issue.23
, pp. 4549-4554
-
-
Hsueh, E.C.1
Essner, R.2
Foshag, L.J.3
|